Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report.

IF 7.6 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-02 DOI:10.1007/s00259-025-07601-8

Oliver Lindner,J Bucerius,B Burchert,T Derlin,R R Buechel

{"title":"Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report.","authors":"Oliver Lindner,J Bucerius,B Burchert,T Derlin,R R Buechel","doi":"10.1007/s00259-025-07601-8","DOIUrl":null,"url":null,"abstract":"PURPOSE\r\nBone scintigraphy using technetium-99 m-labelled phosphonates is increasingly applied for imaging of cardiac transthyretin (ATTR) amyloidosis. However, there is limited data on how frequently this technique is used.\r\n\r\nMATERIALS AND METHODS\r\nTo address this issue, we added questions about the number of patients referred for nuclear medicine scanning for suspected cardiac amyloidosis and the proportion of positive results (Perugini score of 2 or 3) to the 2024 survey on myocardial perfusion imaging conducted jointly in Germany, Austria and Switzerland.\r\n\r\nRESULTS\r\nThe number of participating institutions in Austria, Germany and Switzerland was 12, 170 and 16, respectively. The number of patients scanned for cardiac amyloidosis was 1487, 4029 and 824 with a positivity-rate of 41%, 37% and 49%.\r\n\r\nCONCLUSION\r\nThe survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"114 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07601-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

PURPOSE Bone scintigraphy using technetium-99 m-labelled phosphonates is increasingly applied for imaging of cardiac transthyretin (ATTR) amyloidosis. However, there is limited data on how frequently this technique is used. MATERIALS AND METHODS To address this issue, we added questions about the number of patients referred for nuclear medicine scanning for suspected cardiac amyloidosis and the proportion of positive results (Perugini score of 2 or 3) to the 2024 survey on myocardial perfusion imaging conducted jointly in Germany, Austria and Switzerland. RESULTS The number of participating institutions in Austria, Germany and Switzerland was 12, 170 and 16, respectively. The number of patients scanned for cardiac amyloidosis was 1487, 4029 and 824 with a positivity-rate of 41%, 37% and 49%. CONCLUSION The survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.

查看原文本刊更多论文

2021年至2024年奥地利、德国和瑞士经甲状腺素型心脏淀粉样变性诊断的闪烁成像一份调查报告。

目的利用锝- 99m标记膦酸盐骨显像技术越来越多地应用于心脏转甲状腺素（ATTR）淀粉样变的成像。然而，关于这种技术的使用频率的数据有限。为了解决这一问题，我们在德国、奥地利和瑞士联合进行的2024年心肌灌注成像调查中，增加了疑似心脏淀粉样变的核医学扫描患者数量和阳性结果比例（Perugini评分为2或3分）的问题。结果奥地利12所，德国170所，瑞士16所。心脏淀粉样变性扫描1487例、4029例和824例，阳性率分别为41%、37%和49%。调查数据显示，从2021年到2024年，对心脏淀粉样变性的诊断越来越多，在所有三个国家都观察到类似的趋势。2024年的平均阳性率接近40%，而2021年约为33%。从2021年到2024年，所有参与者的结果表明，转诊医生的预选有所改善，但核医学医生的意识和培训也有所提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Nuclear Medicine and Molecular Imaging 医学-核医学

CiteScore

15.60

自引率

9.90%

发文量

392

审稿时长

3 months

期刊介绍： The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.